MedTrace Logo

A Phase 3 Study of TVP-1012 (1 mg) in Early Parkinson's Disease Patients

NCT02337725 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 244

Last updated 2022-03-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of TVP-1012 (1 mg/day) administered to Japanese patients with early Parkinson's disease.

Conditions

Interventions

DRUG

TVP-1012

TVP-1012 1mg Tablets

DRUG

Placebo

Placebo tablets

Sponsors & Collaborators

Principal Investigators

  • Study Director · Takeda

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-02-07
Primary Completion
2016-09-15
Completion
2016-09-15

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02337725 on ClinicalTrials.gov